Rezolute, Inc (RZLT)

Etorro trading 970x250
Rezolute, Inc (RZLT) Logo

About Rezolute, Inc

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company’s lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California. Address: 201 Redwood Shores Parkway, Redwood City, CA, United States, 94065

Rezolute, Inc News and around…

Latest news about Rezolute, Inc (RZLT) common stock and company :

12 Health Care Stocks Moving In Thursday's After-Market Session
02 Dec, 2021 FinancialContent

Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares rose 7.38% to $1.6 during Thursday's after-market session. The market value of ...

Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress
12 Nov, 2021 Yahoo! Finance

REDWOOD CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the first quarter of fiscal 2022 ended September 30, 2021. “This has been a productive quarter of execution for Rezolute, with steady clinical advancement of our lead pipeline candidates, RZ358 and RZ402, in Phase 2b and Phase

InvestorNewsBreaks – Rezolute Inc. (NASDAQ: RZLT) Announces Underwritten Public Offering, Concurrent Registered Direct Offering
01 Nov, 2021 FinancialContent
Do Institutions Own Rezolute, Inc. (NASDAQ:RZLT) Shares?
19 Oct, 2021 Yahoo! Finance

A look at the shareholders of Rezolute, Inc. ( NASDAQ:RZLT ) can tell us which group is most powerful. Large companies...

50 Biggest Movers From Yesterday
14 Oct, 2021 FinancialContent

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
13 Oct, 2021 FinancialContent

Gainers Statera BioPharma (NASDAQ:STAB) shares increased by 16.92% to $3.16 during Wednesday's regular session. The ...

40 Stocks Moving In Wednesday's Mid-Day Session
13 Oct, 2021 FinancialContent

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock ...

Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
13 Oct, 2021 Yahoo! Finance

REDWOOD CITY, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced the pricing of an underwritten public offering of 6,030,847 shares of its common stock at a public offering price of $6.50 per share and of pre-funded warrants to purchase 1,661,461 shares of its common stock at a public o

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
12 Oct, 2021 Yahoo! Finance

REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, and, in lieu of common stock, Rezolute intends to offer and sell to certain investors pre-funded warrants to purchase shares

Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021
22 Sep, 2021 FinancialContent
Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress
15 Sep, 2021 FinancialContent
Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism
09 Sep, 2021 FinancialContent
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
07 Sep, 2021 FinancialContent
Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME
10 Aug, 2021 FinancialContent
12 Health Care Stocks Moving In Thursday's Intraday Session
15 Jul, 2021 FinancialContent

Gainers Nkarta (NASDAQ:NKTX) shares moved upwards by 8.03% to $30.0 during Thursday's regular session. The current ...

Rezolute Added to Russell Microcap® Index
28 Jun, 2021 FinancialContent
55 Biggest Movers From Friday
28 Jun, 2021 FinancialContent

Gainers IKONICS Corporation (NASDAQ: IKNX) shares surged 64.3% to close at $18.56 on Friday after the company reported a merger ...

12 Health Care Stocks Moving In Friday's Intraday Session
25 Jun, 2021 FinancialContent

Gainers Osmotica Pharmaceuticals (NASDAQ:OSMT) stock increased by 39.78% to $3.97 during Friday's regular session. ...

Oppenheimer Bets on These 2 Stocks; Sees at Least 80% Upside Ahead
25 Jun, 2021 Yahoo! Finance

The stock markets are responding to conflicting signals lately, and the result is concurrent trends of volatility and gains that have been causing some confusion. Inflation has ticked up in recent months, as pent-up demand now let loose by the economic reopening is crossing limited supply and still-disrupted distribution chains. But there’s a strong feeling that the inflation is transitory, and that as people get back to work the inflationary trends will be pushed back by improved production and

Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely?
03 Jun, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. Indeed, Rezolute ( NASDAQ:RZLT ) stock...

68 Biggest Movers From Yesterday
02 Jun, 2021 FinancialContent

Gainers Orbital Energy Group, Inc. (NASDAQ: OEG) shares surged 115.2% to close at $7.64 on Tuesday after the company announced its ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
01 Jun, 2021 FinancialContent

Gainers Nuwellis (NASDAQ:NUWE) stock increased by 22.88% to $4.94 during Tuesday's regular session. The current volume of 3.5 million ...

36 Stocks Moving In Tuesday's Mid-Day Session
01 Jun, 2021 FinancialContent

Gainers Orbital Energy Group, Inc. (NASDAQ: OEG) shares jumped 67.3% to $5.94 after the company announced its subsidiary, Gibson ...

3 ‘Strong Buy’ Stocks with 100% Upside Potential
31 May, 2021 Yahoo! Finance

Every stock investor wants a strong return; that’s axiomatic, it’s why people get into the stock market to begin with. But the markets are inherently risky, and finding the sweet spot – the right combination of risk and reward – seems as much an art as a science. You can use science, however, to minimize the risk. We’re talking about statistical science, the study of numbers, their patterns, and the relationships between them. This can give investors an objective view of the broader market or specific stocks, and can even be used to measure the success of those artists of the stock market, the professional traders and analysts. We’ve used the tools on the TipRanks platform to sort through the publicly traded stocks and find three that are showing a solid combination of risk and reward. Specifically, we’ve looked for Strong Buy stocks that have recently received a thumbs up from an analyst – along with a price target suggesting 100% or better upside potential. Doubling your money sounds like a good return, so let’s find out what else these stocks have going for them. Rezolute (RZLT) We’ll start in the biopharmaceutical industry, where Rezolute specializes in developing drug therapies – new medications – for patients with difficult-to-treat metabolic conditions. These are frequently considered orphan diseases, illnesses that have very few patients and therefore a limited market. Rezolute is currently working on two pipeline projects, both for conditions similar to or related to diabetes. The company’s leading drug candidate, RZ358, in currently undergoing a Phase 2b open-label study as a treatment for congenital hyperinsulinism (CHI), a rare pediatric disorder in which the pancreas produces too much insulin, causing extremely low blood sugar, with cascading effects on the whole body. RZ402, the second drug candidate, is in Phase 1 clinical trials. It is an orally dosed treatment for diabetic macular edema, one of the causes of diabetic-related blindness. In its recent financial report for fiscal Q3 2021, Rezolute included development updates on both leading drug candidates. For RZ358, the company noted that the Phase 2b RIZE study is still enrolling patients and that top line data is expected to become available in 2H21. For the Phase 1 study of RZ402, Resolute announced that the trial is complete and that the initial results demonstrated that once-daily oral dosing is feasible. The company will initiate a Phase 1b trial in 3Q21, as a step toward Phase 2 studies. In financial results, Rezolute reported having on hand $32 million available in cash and equivalents, enough to fund operations into the third calendar quarter of 2022. H.C. Wainwright’s five-star analyst Douglas Tsao initiated his coverage of RZLT with an upbeat outlook, writing, “Rezolute is ready to enter the spotlight with two assets featuring novel mechanisms… Despite assets with promising data and differentiated mechanisms, Rezolute has largely been overlooked by the investment community, which we largely attribute to its entry into the public markets via a reverse merger and an OTC listing. However, with key catalysts upcoming and a recent up listing on the NASDAQ, we think it’s time for investors to pay attention to this story.” Tsao gives the stock a Buy rating and $21 price target that implies an upside of 103% for the coming year. (To watch Tsao’s track record, click here.) The Strong Buy consensus rating on RZLT shares is based on 3 recent reviews – and they are all positive, making the consensus unanimous. The shares are priced at $10.33, with a $25.33 average price target, making the one-year upside potential a robust 145%. (See Rezolute’s stock analysis at TipRanks.) Westport Fuel Systems, Inc. (WPRT) Next up we have Westport Fuel Systems, a company which operates in the green sector of the energy and transportation industry, producing natural gas engines and associated fuel system components, for both personal and commercial vehicles. Westport is a leader in high-pressure direct-injection technology, and also produces engines designed for propane or hydrogen fuels. Westport holds 1,400 patents or patent applications related to alternative fuel systems. Last year, the company made sales in 70 countries, for total revenue of $252 million. In the first quarter report for the current year, Westport posted revenues of $76.4 million, beating the estimates by $3.81 million and up 14% from 1Q20, putting the company on track to beat last year’s total. The company ran a net loss in Q1; however, despite missing the Street’s forecast by $0.01, the loss of 2 cents per share was far lower than the 12-cent loss posted in the year-ago quarter. Westport has a stated goal of reaching $1 billion in annual business by the middle part of this decade. Amit Dayal, 5-star analyst with H.C. Wainwright, covers this stock, and he was impressed by the Q1 results. Dayal wrote, “The YoY strength in revenues is attributed to 25.0% increase in OEM sales supported by demand for light-duty vehicles. Gross margins for the quarter improved to 17.0% compared to 15.5% in 4Q20 supported by product mix.” Turning to the company's outlook, the analyst added, “An important takeaway from the call was management's increasing focus on driving growth in North America. We believe regulatory drivers in this geography are now pressuring fleet owners to seek out cleaner emission trucks. This, in our opinion, plays into the company's available solutions that are already addressing this need.” In-line with those comments, Dayal rated WPRT shares as a Buy. His price target, at $16, indicates confidence in a 155% upside for the nest 12 months. (To watch Dayal’s track record, click here.) Like RZLT above, Westport has received 3 positive stock reviews for a unanimous Strong Buy consensus rating. WPRT shares have an average price target of $13.33, implying a one-year upside of 112% from the current trading price of $6.26. (See Westport’s stock analysis at TipRanks.) Ayr Wellness (AYRWF) For the last stock on our list, we’ll turn to the fast-growing cannabis industry. Ayr Wellness is a US-based cannabis company, an MSO (multistate operator) with operations stretching from the cultivation of the plants to the distribution of the product. Ayr has dispensaries in Arizona, Florida, Massachusetts, Nevada, and Pennsylvania, and offers a range of products for both medicinal and recreational users. The legal cannabis market is young, and still growing quickly. In Ayr’s 1Q21 report, the company showed a 74% year-over-year gain in revenue, to $58.4 million. Ayr has been focusing on expanding its footprint. During the quarter, it closed on the acquisition of Liberty Health Sciences in Florida. This move added 42 dispensaries to Ayr’s Florida operation, giving the company the fourth-largest ‘cannabis footprint’ in the third-largest state. Ayr also closed on acquisitions in Arizona and Ohio, with the Ohio ops slated to begin next quarter. The company expects to enter the New Jersey market by the end of the summer. Echelon analyst Andrew Semple sees the company’s expansion as the driving force here, and he writes of Ayr, “We forecast steep growth ahead, with our forecast calling for sales to surpass $120M by Q420, more than double Q121 levels. In the quarters ahead, Ayr will benefit from first full quarter of contribution from its acquired Arizona and Florida businesses, closing of the Garden State Dispensary acquisition in New Jersey (expected Q321), significant capacity expansions across Arizona, Pennsylvania, Florida, New Jersey, and Nevada (as well as MA/OH to turn online in 2022), and 14 new dispensaries in operation by YE 2021 relative to QE Q121.” Semple, a 5-star analyst rated among the top 100 analysts on Wall Street, gives the shares a Buy rating and bumps his price target up from $C70 ($58) to C$74 ($61) suggesting a 100% upside for the year ahead. (To watch Semple’s track record, click here.) There are 5 recent reviews on this stock, with a breakdown of 4 to 1 in favor of Buy versus Hold, all coalescing to a Strong Buy consensus rating. The average price target stands at $45.58, implying an upside of 49% in the year ahead. (See Ayr Wellness’s stock analysis at TipRanks To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

60 Biggest Movers From Yesterday
28 May, 2021 FinancialContent

Gainers Vertex Energy, Inc. (NASDAQ: VTNR) shares climbed 124.2% to settle at $3.99 on Thursday after the company announced plans ...

Mid-Afternoon Market Update: Dow Surges Over 100 Points; NextGen Healthcare Shares Plunge
27 May, 2021 FinancialContent

Toward the end of trading Thursday, the Dow traded up 0.34% to 34,439.88 while the NASDAQ rose 0.23% to 13,770.24. The S&P also ...

5 Top Health Care Stocks To Watch Ahead Of June 2021
27 May, 2021 FinancialContent
Mid-Day Market Update: Anaplan Drops After Q1 Earnings; Vertex Energy Shares Surge
27 May, 2021 FinancialContent

Midway through trading Thursday, the Dow traded up 0.36% to 34,445.97 while the NASDAQ rose 0.14% to 13,757.62. The S&P also rose, ...

41 Stocks Moving In Thursday's Mid-Day Session
27 May, 2021 FinancialContent

Gainers 1847 Goedeker Inc. (NYSE: GOED) shares jumped 156.5% to $11.08 after dropping over 8% on Wednesday. Vertex Energy, Inc. ...

Mid-Morning Market Update: Markets Mostly Higher; Dollar Tree Profit Tops Estimates
27 May, 2021 FinancialContent

Following the market opening Thursday, the Dow traded up 0.63% to 34,538.05 while the NASDAQ fell 0.02% to 13,735.33. The S&P also ...

Rezolute, Inc (RZLT) is a NASDAQ Common Stock listed in , ,

970x250